Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12623000661673
Ethics application status
Approved
Date submitted
17/04/2023
Date registered
19/06/2023
Date last updated
19/06/2023
Date data sharing statement initially provided
19/06/2023
Type of registration
Prospectively registered
Titles & IDs
Public title
Can Semaglutide or empagliflozin stabilise coronary atherosclerosis in people with type 2 diabetes after acute coronary syndrome
Query!
Scientific title
The "Can Semaglutide or eMpAgliflozin Stabilise coronary atHerosclerosis after Acute Coronary Syndrome (SMASH-ACS)” study in people with type 2 diabetes
Query!
Secondary ID [1]
309468
0
2022-CP-Heart-010-8310
Query!
Universal Trial Number (UTN)
U1111-1287-6009
Query!
Trial acronym
SMASH-ACS
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Type 2 diabetes
329731
0
Query!
Coronary atherosclerosis
329732
0
Query!
Condition category
Condition code
Cardiovascular
326629
326629
0
0
Query!
Coronary heart disease
Query!
Metabolic and Endocrine
326630
326630
0
0
Query!
Diabetes
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
This will be a prospective, randomised, open, blinded end-point (PROBE)-designed trial.
Semaglutide (a glucagon-like peptide-1 receptor agonist (GLP-1 RA) will be self-administered subcutaneously by the patient (starting at 0.25mg/week, uptitrated on a monthly basis based on patient tolerance and at the direction of a physician, up to 1.0 mg/week as tolerated) in an open label manner.
Participants will undergo a baseline CT coronary angiogram (CTCA), continue on the treatment for 12 months, and then undergo a repeat CTCA.
Adherence will be assessed by patient report at 1, 2, 3, 6, 9, and 12 months.
Query!
Intervention code [1]
325894
0
Treatment: Drugs
Query!
Comparator / control treatment
The comparator will be empagliflozin (a sodium-glucose co-transporter-2 (SGLT2) inhibitor), at a starting dose of 10mg daily, which can be uptitrated to 25mg daily at 3 months at clinician discretion, in an open label manner.
Participants will undergo a baseline CT coronary angiogram (CTCA), continue on the treatment for 12 months, and then undergo a repeat CTCA.
Adherence will be assessed by patient report at 1, 2, 3, 6, 9, and 12 months.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
334497
0
Progression rates of low attenuation plaque under influence of GLP-1 RA as compared to SGLT2 inhibition as assessed by CT coronary angiography
Query!
Assessment method [1]
334497
0
Query!
Timepoint [1]
334497
0
Baseline and 12 months post-commencement of treatment
Query!
Secondary outcome [1]
420874
0
Change in total non-calcified plaque volume as assessed by CT coronary angiography
Query!
Assessment method [1]
420874
0
Query!
Timepoint [1]
420874
0
Baseline and 12 months post-commencement of treatment
Query!
Secondary outcome [2]
420886
0
Change in HbA1c from baseline as assessed by serum HbA1c measurement
Query!
Assessment method [2]
420886
0
Query!
Timepoint [2]
420886
0
Baseline and 12 months post-commencement of treatment
Query!
Secondary outcome [3]
420887
0
Change in renal function as assessed by serum creatinine from baseline
Query!
Assessment method [3]
420887
0
Query!
Timepoint [3]
420887
0
Baseline and 12 months post-commencement of treatment
Query!
Secondary outcome [4]
420888
0
Change in weight as assessed by a digital scale
Query!
Assessment method [4]
420888
0
Query!
Timepoint [4]
420888
0
Baseline and 12 months post-commencement of treatment
Query!
Secondary outcome [5]
420889
0
Change in blood pressure from baseline as measured by non-invasive blood pressure measurements obtained using a manual sphygmomanometer
Query!
Assessment method [5]
420889
0
Query!
Timepoint [5]
420889
0
Baseline and 12 months post-commencement of treatment
Query!
Secondary outcome [6]
420890
0
Change in high sensitivity C-reactive protein from baseline using serum high sensitivity C-reactive protein
Query!
Assessment method [6]
420890
0
Query!
Timepoint [6]
420890
0
Baseline and 12 months post-commencement of treatment
Query!
Secondary outcome [7]
420891
0
Change in lipid profile composition from baseline using serum lipid profile (total cholesterol, high-density lipoprotein, low-density lipoprotein, and triglyceride measurements)
Query!
Assessment method [7]
420891
0
Query!
Timepoint [7]
420891
0
Baseline and 12 months post-commencement of treatment
Query!
Secondary outcome [8]
420892
0
Assess change in quality of life from baseline as assessed by the SF36v2 questionnaire
Query!
Assessment method [8]
420892
0
Query!
Timepoint [8]
420892
0
Baseline, 6 months and 12 months post-commencement of treatment
Query!
Secondary outcome [9]
420893
0
Assess change in diabetic distress compared with baseline as assessed using a composite of the Diabetes Distress Screening Scale and PHQ-9 questionnaires
Query!
Assessment method [9]
420893
0
Query!
Timepoint [9]
420893
0
Baseline, 6 months and 12 months post-commencement of treatment
Query!
Secondary outcome [10]
420894
0
Evaluate changes in coronary artery shear stress as evaluated by CTCA from baseline
Query!
Assessment method [10]
420894
0
Query!
Timepoint [10]
420894
0
Baseline and 12 months post-commencement of treatment
Query!
Secondary outcome [11]
420895
0
Evaluate autophagy at baseline and after 12 months of study drug administration assessed using peripheral blood mononuclear cells with an ELISA-based assay
Query!
Assessment method [11]
420895
0
Query!
Timepoint [11]
420895
0
Baseline and 12 months post-commencement of treatment
Query!
Secondary outcome [12]
422549
0
Calcified coronary plaque volume as assessed. by CTCA
Query!
Assessment method [12]
422549
0
Query!
Timepoint [12]
422549
0
Baseline and 12 months post-commencement of treatment
Query!
Secondary outcome [13]
422550
0
Percent coronary atheroma volume as assessed. by CTCA
Query!
Assessment method [13]
422550
0
Query!
Timepoint [13]
422550
0
Baseline and 12 months post-commencement of treatment
Query!
Secondary outcome [14]
422551
0
Maximum lumen stenosis as assessed. by CTCA
Query!
Assessment method [14]
422551
0
Query!
Timepoint [14]
422551
0
Baseline and 12 months post-commencement of treatment
Query!
Secondary outcome [15]
422552
0
Leaman score as assessed. by CTCA
Query!
Assessment method [15]
422552
0
Query!
Timepoint [15]
422552
0
Baseline and 12 months post-commencement of treatment
Query!
Secondary outcome [16]
422553
0
Pericoronary adipose tissue attenuation as assessed. by CTCA
Query!
Assessment method [16]
422553
0
Query!
Timepoint [16]
422553
0
Baseline and 12 months post-commencement of treatment
Query!
Secondary outcome [17]
422554
0
Epicardial fat volume as assessed by CTCA
Query!
Assessment method [17]
422554
0
Query!
Timepoint [17]
422554
0
Baseline and 12 months post-commencement of treatment
Query!
Secondary outcome [18]
422555
0
Assess change in gastro-intestinal autonomic function from baseline as assessed by the PAGI-SYM questionnaire
Query!
Assessment method [18]
422555
0
Query!
Timepoint [18]
422555
0
Baseline, 6 months and 12 months post-commencement of treatment
Query!
Secondary outcome [19]
422556
0
Assess change in genitourinary autonomic function from baseline as assessed by International Index of Erectile Function (IIEF) questionnaire
Query!
Assessment method [19]
422556
0
Query!
Timepoint [19]
422556
0
Baseline, 6 months and 12 months post-commencement of treatment
Query!
Secondary outcome [20]
422557
0
Assess change in mental well being from baseline as assessed using a self-developed questionnaire
Query!
Assessment method [20]
422557
0
Query!
Timepoint [20]
422557
0
Baseline, 6 months and 12 months post-commencement of treatment
Query!
Secondary outcome [21]
422558
0
Assess change in non-cardiac pain as assessed by the self-developed questionnaires
Query!
Assessment method [21]
422558
0
Query!
Timepoint [21]
422558
0
Baseline, 6 months and 12 months post-commencement of treatment
Query!
Secondary outcome [22]
422872
0
Assess change in quality of life from baseline as assessed by the AQoL 8D questionnaire
Query!
Assessment method [22]
422872
0
Query!
Timepoint [22]
422872
0
Baseline, 6 months and 12 months post-commencement of treatment
Query!
Secondary outcome [23]
422873
0
Change in renal function as assessed by eGFR from baseline
Query!
Assessment method [23]
422873
0
Query!
Timepoint [23]
422873
0
Baseline and 12 months post-commencement of treatment
Query!
Secondary outcome [24]
422993
0
Epicardial fat density as assessed by CTCA
Query!
Assessment method [24]
422993
0
Query!
Timepoint [24]
422993
0
Baseline and 12 months post-commencement of treatment
Query!
Secondary outcome [25]
422994
0
Assess change in gastro-intestinal autonomic function from baseline as assessed by the diabetes bowel symptom survey questionnaire
Query!
Assessment method [25]
422994
0
Query!
Timepoint [25]
422994
0
Baseline, 6 months and 12 months post-commencement of treatment
Query!
Secondary outcome [26]
422995
0
Assess change in genitourinary autonomic function from baseline as assessed by the International Prostate Symptom Score (IPSS) score
Query!
Assessment method [26]
422995
0
Query!
Timepoint [26]
422995
0
Baseline, 6 months and 12 months post-commencement of treatment
Query!
Secondary outcome [27]
422996
0
Assess change in genitourinary autonomic function from baseline as assessed by the ICIQ-IU short form questionnaire
Query!
Assessment method [27]
422996
0
Query!
Timepoint [27]
422996
0
Baseline, 6 months and 12 months post-commencement of treatment
Query!
Eligibility
Key inclusion criteria
- Hospitalisation with an acute coronary syndrome (as defined by the 2020 European Society of Cardiology (ESC) Guidelines for the Management of Acute Coronary Syndromes), where participant has undergone invasive coronary angiography and is left with residual atherosclerotic stenoses in one or more coronary arteries of at least 20% severity that will be left for medical management with no intention to revascularise by stenting or bypass grafting in the next 12 months
- Previous or new (in hospital) diagnosis of type 2 diabetes
- No contraindication to glucagon-like peptide-1 receptor agonists (GLP-1 RA) or sodium glucose co-transporter-2 (SGLT2) inhibitor usage (see key exclusion criteria)
- Eligible to use either GLP-1 RA or SGLT2 inhibitor as per PBS criteria (in summary, patients must have type 2 diabetes, and be on treatment with metformin and/or sulfonylurea as tolerated, and have a HbA1c >7%)
- Willing to use injectable medication
- Willingness to be on birth control for women of childbearing age or established post-menopausal
- Participants are required to have undergone screening, enrolment, baseline imaging and randomisation and drug initiation within 30 days of their index admission for their acute coronary syndrome
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Contraindication to GLP-1 RA use, including history of pancreatitis (acute or chronic), and established retinopathy
- Contraindication to SGLT2 inhibitor use, including recurrent genitourinary infections, and history of ketoacidosis
- Known history of a clinically significant gastric emptying abnormality, such as severe gastroparesis or gastric outlet obstruction, or being planned for bariatric surgery within the next 12 months
- Left ventricular ejection fraction <=35% or New York Heart Association (NYHA) class IV heart failure
- A personal or family history of medullary thyroid carcinoma, or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- Known type 1 diabetes
- Prior/known intolerance of GLP-1 receptor agonists or SGLT2 inhibitors
- Concurrent DPP4 use or use within the 2 weeks prior to randomisation occurring
- Dialysis or estimated glomerular filtration rate (eGFR) <30 ml/min/1.73m2
- Previous or planned coronary artery bypass grafting
- Pregnant women or women planning pregnancy in the following 12 months
- Life expectancy <1year
- Contraindications to CT coronary angiography
- Concurrent enrolment in another placebo-controlled trial or within 30 days of finishing another trial
- Enrolment and participation in another trial involving ionising radiation in the last 12 months
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation concealment will occur, with central randomisation performed by computer
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
An intention-to-treat analysis will be the primary analysis. For the primary outcome, the change in low attenuation plaque (LAP) volume will be compared between the treatment groups using a linear regression model, adjusting for the baseline measurement and the stratification variables. Secondary outcomes will be analysed similarly using linear regression models for continuous outcomes and logistic regression models for binary outcomes.
Per protocol analysis will be performed on those with treatment compliance >80% as a sensitivity analysis. P-values of <0.05 will be considered statistically significant.
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
17/07/2023
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
132
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
SA
Query!
Funding & Sponsors
Funding source category [1]
313665
0
Charities/Societies/Foundations
Query!
Name [1]
313665
0
The Hospital Research Foundation
Query!
Address [1]
313665
0
Level 1, 62 Woodville Road, Woodville, SA 5011
Query!
Country [1]
313665
0
Australia
Query!
Primary sponsor type
Other Collaborative groups
Query!
Name
South Australian Health and Medical Research Institute
Query!
Address
North Terrace, Adelaide SA 5000
Query!
Country
Australia
Query!
Secondary sponsor category [1]
315467
0
None
Query!
Name [1]
315467
0
Query!
Address [1]
315467
0
Query!
Country [1]
315467
0
Query!
Other collaborator category [1]
282632
0
Hospital
Query!
Name [1]
282632
0
Royal Adelaide Hospital
Query!
Address [1]
282632
0
Port Road, Adelaide SA 5000
Query!
Country [1]
282632
0
Australia
Query!
Other collaborator category [2]
282633
0
Hospital
Query!
Name [2]
282633
0
Flinders Medical Centre
Query!
Address [2]
282633
0
Flinders Drive, Bedford Park SA 5042
Query!
Country [2]
282633
0
Australia
Query!
Other collaborator category [3]
282634
0
Hospital
Query!
Name [3]
282634
0
The Queen Elizabeth Hospital
Query!
Address [3]
282634
0
28 Woodville Rd, Woodville South SA 5011
Query!
Country [3]
282634
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
312830
0
Central Adelaide Local Health Network Human Research Ethics Committee
Query!
Ethics committee address [1]
312830
0
CALHN Research Services, Central Adelaide Local Health Network Inc., SA Health
Level 3, Roma Mitchell Building, 136 North Terrace, Adelaide, SA 5000
Query!
Ethics committee country [1]
312830
0
Australia
Query!
Date submitted for ethics approval [1]
312830
0
11/04/2023
Query!
Approval date [1]
312830
0
31/05/2023
Query!
Ethics approval number [1]
312830
0
2023/HRE00023
Query!
Summary
Brief summary
Type 2 diabetes mellitus (T2DM) is a chronic disease, the prevalence of which is rapidly growing world-wide. As a result of historical concerns of the safety of available glucose-lowering therapies, cardiovascular outcome trials (CVOTs) were mandated by the Food and Drug Administration (FDA) in 2008 to ensure that new anti-diabetic therapies coming onto the market were safe from a cardiovascular perspective. Out of the recently studied drug classes, GLP-1 receptor agonists (GLP-1 RAs) and sodium-glucose co-transporter 2 (SGLT2) inhibitors have both shown to provide cardiovascular benefits, not just safety/non-inferiority compared to the more traditional glucose-lowering agents they have been compared to. Both are currently recommended in guidelines for use in patients with a cardiac history, however, it is not clear whether one would confer a greater benefit than the other in patients who have recently had an acute coronary syndrome (ACS), nor whether they can slow plaque progression, as a possible mechanism of their cardiovascular benefit. Given patients in Australia can only access one therapy at a time on the PBS, any information regarding their direct comparison in this patient population would be useful.
This will be a prospective, randomised, open, blinded end-point (PROBE)-designed trial that will evaluate the effect of semaglutide and empagliflozin on coronary plaque, as assessed by computer tomography coronary angiography (CTCA) at baseline and following 12 months of treatment with either semaglutide or empagliflozin in participants with diabetes and known coronary artery disease who have presented with an acute coronary syndrome.
We hypothesise that participants prescribed semaglutide will have a slower progression in coronary plaque development as compared with participants on empagliflozin.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
126070
0
A/Prof Peter Psaltis
Query!
Address
126070
0
South Australian Health and Medical Research Institute
Port Rd
Adelaide SA 5000
Query!
Country
126070
0
Australia
Query!
Phone
126070
0
+61 8 8128 4710
Query!
Fax
126070
0
Query!
Email
126070
0
[email protected]
Query!
Contact person for public queries
Name
126071
0
Dr Jessica Marathe
Query!
Address
126071
0
Royal Adelaide Hospital
Port Rd
Adelaide SA 5000
Query!
Country
126071
0
Australia
Query!
Phone
126071
0
+61 8 7074 6182
Query!
Fax
126071
0
Query!
Email
126071
0
[email protected]
Query!
Contact person for scientific queries
Name
126072
0
Dr Jessica Marathe
Query!
Address
126072
0
Royal Adelaide Hospital
Port Rd
Adelaide SA 5000
Query!
Country
126072
0
Australia
Query!
Phone
126072
0
+61 8 7074 6182
Query!
Fax
126072
0
Query!
Email
126072
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF